🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

Recruitingn/aAges 18 Years - 45 YearsFemaleAmmar Jassim Abed
NCT07349277 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
IInclusion Criteria: * Pregnant women between 20 and 36 weeks of gestation * Age between 18 and 45 years * Attending the antenatal clinic at the study site Exclusion Criteria: * Chronic hypertension * Renal disease * Diabetes mellitus * Multiple gestations * Autoimmune disorders
💊

What it tests

  • Not listed
📍

Where

1 site
Bint Al Huda Maternity Hospital
Nasiriyah, Iraq
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy